Global Insulin Glargine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Insulin Glargine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

nsulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).

According to our (Global Info Research) latest study, the global Insulin Glargine market size was valued at US$ 7202 million in 2023 and is forecast to a readjusted size of USD 9390 million by 2030 with a CAGR of 3.9% during review period.

Global Insulin Glargine key players include Sanofi-Aventis, Ganlee, etc. Global top two manufacturers hold a share nearly 50%.

USA is the largest market, with a share over 60%, followed by China, and Europe, both have a share about 35 percent.

In terms of product, Pre-filled Syringe is the largest segment, with a share about 75%. And in terms of application, the largest application is Treat type2 diabetes, followed by Treat type1 diabetes.

This report is a detailed and comprehensive analysis for global Insulin Glargine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Insulin Glargine market size and forecasts, in consumption value ($ Million), sales quantity (M mL), and average selling prices (USD/mL), 2019-2030

Global Insulin Glargine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M mL), and average selling prices (USD/mL), 2019-2030

Global Insulin Glargine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M mL), and average selling prices (USD/mL), 2019-2030

Global Insulin Glargine market shares of main players, shipments in revenue ($ Million), sales quantity (M mL), and ASP (USD/mL), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Insulin Glargine

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Insulin Glargine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi-Aventis, Ganlee, Biocon, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Insulin Glargine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Single Dose Vial
Pre-filled Syringe

Market segment by Application
Treat Type2 Diabetes
Treat Type1 Diabetes

Major players covered
Sanofi-Aventis
Ganlee
Biocon

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Insulin Glargine product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Insulin Glargine, with price, sales quantity, revenue, and global market share of Insulin Glargine from 2019 to 2024.

Chapter 3, the Insulin Glargine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Insulin Glargine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Insulin Glargine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Insulin Glargine.

Chapter 14 and 15, to describe Insulin Glargine sales channel, distributors, customers, research findings and conclusion.